MedinCell SA (FR:MEDCL)
:MEDCL
Want to see FR:MEDCL full AI Analyst Report?
Top Page
MedinCell SA
(MEDCL)
Select Model
Select Model
Rating:49Neutral
Price Target:
€20.00
▼(-17.56% Downside)
Action:Upgraded
Date:01/29/26
The score is held back primarily by weak financial performance (large losses and negative equity/leverage risk) and a soft technical setup (below key moving averages with subdued momentum). These are partly offset by a positive earnings-call outlook highlighting regulatory progress, partner-driven commercial growth (UZEDY), and pipeline/milestone potential.
Positive Factors
Strong revenue growth
Sustained top-line expansion near 100% indicates strong commercial traction and partnership-driven royalties (UZEDY). Durable revenue growth improves runway and validates the BEPO® platform's market fit, supporting continued investment in pipeline and de-risking long-term cash generation.
Negative Factors
High leverage and negative equity
Liabilities exceeding assets and significant leverage are structural red flags that constrain strategic flexibility. Negative equity distorts metrics (ROE) and increases refinancing and covenant risk, making long‑term funding and M&A optionality more expensive or uncertain.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong revenue growth
Sustained top-line expansion near 100% indicates strong commercial traction and partnership-driven royalties (UZEDY). Durable revenue growth improves runway and validates the BEPO® platform's market fit, supporting continued investment in pipeline and de-risking long-term cash generation.
Read all positive factors
MedinCell SA (MEDCL) vs. iShares MSCI France ETF (EWQ)
Market Cap
€899.80M
Dividend YieldN/A
Average Volume (3M)179.66K
Price to Earnings (P/E)―
Beta (1Y)0.91
Revenue Growth-23.21%
EPS Growth-46.17%
CountryFR
Employees131
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.61
Shares Outstanding35,910,046
10 Day Avg. Volume204,359
30 Day Avg. Volume179,664
Financial Highlights & Ratios
PEG Ratio0.80
Price to Book (P/B)-25.60
Price to Sales (P/S)16.41
P/FCF Ratio23.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€35.50Price Target Upside46.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.02
Revenue Forecast (FY)€48.88M
MedinCell SA Business Overview & Revenue Model
Company Description
MedinCell S.A. specializes in pioneering diverse therapeutic treatments. At the core of its development lies BEPO, a cutting-edge technology that enables the creation of long-acting injectable pharmaceutical products. This system leverages a uniqu...
How the Company Makes Money
MedinCell primarily makes money by partnering its BEPO® long-acting injectable technology with other pharmaceutical companies’ active ingredients and by participating in the downstream economics of partnered products. Key revenue streams include: ...
MedinCell SA Earnings Call Summary
Earnings Call Date:Jun 16, 2026
(Q4-2026)
| % Change Since: |
Next Earnings Date:Dec 08, 2026
Earnings Call Sentiment Positive
The call presents a largely positive strategic picture: strong commercial traction for UZEDY with high-teens to double-digit growth rates, clear regulatory progress for olanzapine LAI (NDA accepted) and an expanding partnered pipeline (15 formulation-stage programs, AbbVie program advancing toward clinic). Management is intentionally increasing investment to accelerate R&D and business development, which drove higher operating expenses and resulted in an operating and net loss this fiscal year, and there are near-term accounting and FX headwinds (non-cash EIB warrant revaluation, USD exposure) as well as some program-specific regulatory uncertainty. Overall, the company is in a transitional, investment-heavy phase with improving recurring royalty revenue that supports a positive outlook if commercial ramps and regulatory approvals proceed as expected.Positive Updates
Strong UZEDY Commercial Momentum
Teva-reported net sales for UZEDY reached $250 million in FY 2025/2026 versus $141 million prior year (≈+77%), driving royalty growth to $10.9 million from $7.1 million in USD (≈+54%). Q1 2026 net sales were $63 million, up 62% year-over-year, and Teva provided an initial 2026 guidance range of $250M–$280M with expectations close to $300M for the year.
Negative Updates
FY Revenue Slightly Lower Due to Absent Milestones
Total income for the period was EUR 24.3 million versus EUR 27.7 million the prior year, primarily because no milestone payments were received this year (prior year included a EUR 4.8 million milestone). This creates year-to-year variability tied to one-off events.
Read all updates
Q4-2026 Updates
Positive
Negative
Strong UZEDY Commercial Momentum
Teva-reported net sales for UZEDY reached $250 million in FY 2025/2026 versus $141 million prior year (≈+77%), driving royalty growth to $10.9 million from $7.1 million in USD (≈+54%). Q1 2026 net sales were $63 million, up 62% year-over-year, and Teva provided an initial 2026 guidance range of $250M–$280M with expectations close to $300M for the year.
Read all positive updates
Company Guidance
Management provided detailed forward guidance focused on three growth engines: UZEDY, olanzapine LAI and a broader pipeline. Key metrics: Teva reported UZEDY net sales of $250m in FY2025/26 (vs $141m prior year) driving royalties to $10.9m (+54% YoY in USD; +42% in EUR to €9.3m), Q1‑2026 sales of $63m (+62% YoY), and Teva’s initial 2026 guidance of $250–$280m (management now sees ~ $300m potential for 2026 and expects blockbuster trajectory into the early 2030s). Olanzapine LAI: NDA accepted Feb‑2026 and EU MAA submitted, targeting U.S. launch in Q4‑2026 (first royalties potentially as early as Q4‑2026) with “meaningful” revenues expected from H2‑2027 and a faster ramp than UZEDY. Pipeline/platform metrics: >4,000 subQ injections with no PDSS, 15 programs in formulation (7 internal, 8 partner‑funded), CMC for the AbbVie program completing this year with a clinical start in 2027, and mdc‑CWM Phase‑III prep/initiation expected in 2026. Financial context/guidance drivers: total income €24.3m (vs €27.7m), royalties = 38% of revenue (vs 22% prior year), OpEx €45m (vs €38.5m) with R&D ≈60% of OpEx, operating loss €20.8m, net loss €31.3m, cash €80.8m (net cash €15.3m), €6.4m AbbVie collaboration revenue, €1.6m early‑stage partner revenues, and no milestone this year (prior year included a €4.8m olanzapine milestone).MedinCell SA Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
30
Negative
Cash Flow
50
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 27.71M | 25.54M | 9.16M | 9.94M | 4.09M | 8.19M |
| Gross Profit | 16.11M | 25.54M | 9.16M | 9.94M | 4.09M | 6.74M |
| EBITDA | -18.74M | -11.20M | -18.61M | -26.41M | -21.45M | -15.38M |
| Net Income | -19.95M | -18.44M | -25.04M | -32.01M | -24.81M | -19.02M |
Balance Sheet | ||||||
| Total Assets | 74.58M | 90.45M | 36.95M | 29.34M | 44.30M | 63.61M |
| Cash, Cash Equivalents and Short-Term Investments | 53.50M | 71.90M | 19.46M | 6.47M | 26.59M | 49.87M |
| Total Debt | 58.27M | 58.76M | 58.96M | 57.71M | 47.49M | 43.34M |
| Total Liabilities | 105.21M | 106.82M | 77.77M | 71.63M | 57.67M | 54.69M |
| Stockholders Equity | -30.63M | -16.37M | -40.82M | -42.29M | -13.37M | 8.92M |
Cash Flow | ||||||
| Free Cash Flow | -17.88M | 17.80M | -13.11M | -22.03M | -23.34M | -12.96M |
| Operating Cash Flow | -17.10M | 19.46M | -11.92M | -21.00M | -21.36M | -12.14M |
| Investing Cash Flow | 685.00K | -13.21M | -613.00K | 1.30M | -316.00K | -1.06M |
| Financing Cash Flow | 34.55M | 33.32M | 25.53M | 1.56M | -800.00K | 47.92M |
MedinCell SA Technical Analysis
Negative
24.26
Price Trends
26.02
Negative
24.39
Positive
26.02
Negative
Market Momentum
-0.28
Positive
43.71
Neutral
18.53
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:MEDCL, the sentiment is Negative. The current price of 24.26 is below the 20-day moving average (MA) of 26.81, below the 50-day MA of 26.02, and below the 200-day MA of 26.02, indicating a bearish trend. The MACD of -0.28 indicates Positive momentum. The RSI at 43.71 is Neutral, neither overbought nor oversold. The STOCH value of 18.53 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:MEDCL.
MedinCell SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | €899.80M | -28.97 | ― | ― | -23.21% | -46.17% | |
48 Neutral | €207.11M | -2.85 | -634.16% | ― | 291.43% | 12.24% | |
46 Neutral | €1.54B | -61.02 | ― | ― | ― | ― | |
44 Neutral | €6.85B | -17.73 | ― | ― | ― | ― | |
42 Neutral | €823.48M | -3.37 | -241.12% | ― | ― | 27.51% | |
42 Neutral | €437.14M | -2.84 | -58.93% | ― | -15.98% | -54.34% |
* Healthcare Sector Average
FR:MEDCL
MedinCell SA
26.36
9.81
59.27%
FR:ABVX
Abivax SA
85.65
80.05
1429.46%
FR:DBV
DBV Technologies
2.87
1.36
89.95%
FR:NANO
Nanobiotix
31.12
27.26
705.17%
FR:TNG
Transgene
0.74
-0.13
-15.33%
FR:VLA
Valneva
2.31
-0.09
-3.59%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.